• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

I've Got an Options Bandage for a Sick Economy

Let's see why this diagnostics and therapeutic imaging company might be just what the doctor ordered in an ailing economy.
By BRET JENSEN
Jun 19, 2022 | 07:30 AM EDT
Stocks quotes in this article: GILD, MRK, LNTH, PGNX, NVS

As the economic outlook grows sicker and sicker, one of the areas I am looking to bandage up any potential bleeding is health care. I'm already into Gilead Sciences (GILD)  and Merck (MRK) via covered-call orders, as I wrote earlier on Friday. Now, I'm taking aim at another health care name: Lantheus Holdings (LNTH) .

Financial stressors are already infecting the nation: Consumer demand is ebbing quickly putting retail under distress and feverish interest rates are is giving the housing market chills and cooling durable good concerns like auto manufacturers.

But in times of economic health and sickness, drugs tend to be a fairly recession-resistant.

That's why I'm exploring another covered-call idea in the health care sector. This one is a bit riskier compared to the two drug giants I'm already into, Gilead and Merck. But an investor is compensated for that risk via higher option premiums.

I first became aware of Lantheus Holdings in late 2019 when it purchased Progenics Pharmaceuticals (PGNX)  in an all-stock transaction. I had a fairly large holding in Progenics and it was acquired for a considerable discount to its asset value. Sure enough, Progenics' cancer imaging agent pipeline has paid off for Lantheus in a big way.

Lantheus develops, manufactures and commercializes diagnostic and therapeutic imaging products and artificial intelligence software including those for cancer detection.

The rollout of Pylarify, an imaging agent for prostate cancer that came with the buyout of Progenics, has been more than impressive. After posting sales of just over $35 million in the fourth quarter of last year, sales were up over $90 million in this year's first quarter. This was a key reason that Lantheus crushed top- and bottom-line estimates when it reported first quarter results in late April. The company also took up its full year revenue up by more than $100 million to $800 million to $835 million in fiscal 2022. Leadership believes Pylarify has just over $1 billion in peak annual sales potential. The company is also seeing good growth from some of the other products in its portfolio including Definity, an ultrasound enhancing agent. The company has a robust pipeline in development, and most of its efforts are partnered with larger drugmakers like Novartis (NVS) .

The stock rallied on these earnings, which garnered a couple of analyst "Buy" reiterations. But, with the recent selloff in the market, the shares are back down to where they traded before the big earnings beat right at $60 a share. Recent analyst price targets are in the $90-to-$100-a-share range. Based on guidance, revenues will be up over 90% in fiscal 2022 and the stock sells for 20-times forward profits.

Option Strategy:

This is how one can execute a covered call position in LNTH. Using the November $60 calls, fashion a covered call order with a net debit in the $49.00 to $49.50 range (net stock price - option premium). Options are decently liquid and the order should fill during the day. This strategy provides downside protection of nearly 20% and around 22% of potential upside over the option duration of just five months even if the stock does nothing

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen had positions in GILD, LNTH and MRK.

TAGS: Investing | Options | Stocks | Health Care Equipment & Services

More from Stocks

Even Some Out of Fashion Names Are Now Back in Style

Jonathan Heller
Jan 27, 2023 12:30 PM EST

Sure, we're only one month in to 2023, but so far these stocks are starting the new year with a bang.

I'm Making Small Bets With These 2 Stocks

Bret Jensen
Jan 27, 2023 11:30 AM EST

While I remain cautious on the overall market, I continue to act upon the limited opportunities I'm finding in the current market.

Chevron Is Crushing It and for My Portfolio Too: Here's the Trade

Stephen Guilfoyle
Jan 27, 2023 10:51 AM EST

The only reason to exit the stock now is profit-taking.

Adani Companies Plunge Under Hindenburg Attack, Hurting Secondary Sale Attempt

Alex Frew McMillan
Jan 27, 2023 9:30 AM EST

Retail investors may baulk now they are being offered Adani Enterprises shares at a range well above their current trading price.

Intel Tanks (Again), but I Spy 3 Other Charts That Look Pretty Darn Good

Bob Byrne
Jan 27, 2023 9:00 AM EST

The trio consists of a beverage seller, a connectivity company and a producer of advanced driving system technology.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • 03:06 PM EST BOB LANG

    LEAPS Webinar

    This week, I offered a free webinar session talkin...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login